Zhao Xiang-Yu, Huang Xiao-Jun, Liu Kai-Yan, Xu Lan-Ping, Liu Dai-Hong
Institute of Hematology, People's Hospital of Peking University, Beijing 100044, China.
Zhonghua Xue Ye Xue Za Zhi. 2008 May;29(5):316-20.
To evaluate the prognostic implication of the killer-immunoglobulin like receptor (KIR) ligand mismatch in HLA mismatched hematopoietic stem cell transplantation (HSCT).
Ninety-four leukemia patients undergoing unmanipulated HLA-mismatched/haploidentical blood and marrow HSCT enrolled this study.
Multivariate analysis showed that both KIR ligand mismatch (HR 2.833, CI, 1.286 - 6.241, P = 0.01) and doses of T cells (HR 3.059, CI, 1.292 - 7.246, P = 0.011) were independent risk factors for the acute graft versus host disease (aGVHD). In addition, compared to those without KIR ligand mismatch, patients with KIR ligand mismatch had the more adverse effect of 'high' dose T cells (> 1.48 x 10(5)/kg) on aGVHD (100% vs 63.3%, P = 0.036), and had more incidence of aGVHD with HLA-C mismatch (80.0% vs 57.4%, P = 0.056). Since multivariate analysis demonstrated that high risk leukemia was the only predictor for transplant related mortality (TRM), relapse and overall survival (OS), the effect of KIR ligand mismatch on prognosis in standard and high risk patients was further analyzed. The differences in TRM (50.0% vs 7.6%, P = 0.005) and OS (50.0% vs 88.4%, P = 0.014) between patients with and without KIR ligand mismatch were most striking for standard risk patients.
KIR ligand mismatch is a poor prognosis factor for patients underwent HLA mismatched HSCT, and is a useful parameter for donor selection.
评估杀伤细胞免疫球蛋白样受体(KIR)配体错配在HLA错配造血干细胞移植(HSCT)中的预后意义。
94例接受非处理的HLA错配/单倍体相合血液和骨髓HSCT的白血病患者纳入本研究。
多因素分析显示,KIR配体错配(HR 2.833,CI,1.286 - 6.241,P = 0.01)和T细胞剂量(HR 3.059,CI,1.292 - 7.246,P = 0.011)均为急性移植物抗宿主病(aGVHD)的独立危险因素。此外,与无KIR配体错配的患者相比,有KIR配体错配的患者“高”剂量T细胞(> 1.48 x 10(5)/kg)对aGVHD的不良影响更大(100% 对63.3%,P = 0.036),且HLA - C错配时aGVHD的发生率更高(80.0% 对57.4%,P = 0.056)。由于多因素分析表明高危白血病是移植相关死亡率(TRM)、复发和总生存(OS)的唯一预测因素,因此进一步分析了KIR配体错配在标准风险和高危患者中的预后影响。有和无KIR配体错配患者之间的TRM(50.0% 对7.6%,P = 0.005)和OS(50.0% 对88.4%,P = 0.014)差异在标准风险患者中最为显著。
KIR配体错配是接受HLA错配HSCT患者的不良预后因素,也是供体选择的有用参数。